|
May 22
|
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
|
|
May 22
|
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
|
|
May 22
|
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
|
|
May 21
|
Sanofi to Buy Vigil Neuroscience for About $470 Million
|
|
May 21
|
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
|
|
May 21
|
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
|
|
May 20
|
Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management
|
|
Apr 29
|
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
|
|
Apr 28
|
Private Equity Firms Target Defense Assets Once Seen as Toxic
|
|
Apr 25
|
Swiss Agree to Tariff Negotiations With Trump Administration
|
|
Apr 24
|
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
|
|
Apr 24
|
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
|
|
Apr 24
|
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
|
|
Apr 23
|
Why vaccine makers aren't worried about Trump administration cuts
|
|
Apr 19
|
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
|
|
Apr 18
|
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
|
|
Apr 18
|
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
|
|
Apr 18
|
Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever
|
|
Apr 15
|
Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
|
|
Apr 9
|
Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’
|